Monitor AACR presentation for additional data clarity; assess whether results support upcoming clinical trial design. Preclinical data may provide sentiment uplift but lacks near-term commercial catalyst.
Price Chart
Executive Summary
SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing potent apoptosis induction in AML cell lines, including those with high-risk ASXL1 and TP53 mutations. The data will be presented at the upcoming AACR conference in April 2026, highlighting the drug's mechanism and potential for clinical development in acute myeloid leukemia.
Key Facts
- Preclinical data shows SLS009 induces apoptosis in AML cell lines by reducing MCL-1 and survivin levels.
- IC50 decreased from 50 nM to 20 nM with repeated dosing, indicating enhanced potency.
- Activity observed in AML models with ASXL1 and TP53 mutations, which are linked to poor prognosis.
- Poster presentation scheduled for April 21, 2026, at AACR conference.
- No clinical trial results or regulatory decisions announced — data is preclinical.
Financial Impact
No direct financial impact disclosed; potential long-term value if clinical development succeeds.
Risk Factors
- Preclinical results do not guarantee clinical success.
- No timeline provided for next-stage clinical trials.
- High-risk AML mutations remain difficult to treat despite promising in vitro data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257676 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | Press Release | $11.61 | awaiting T+60 | — | $12.17 (+4.82%) |
Jun 2, 2026 21w ago | 8-K | $8.33 $13.73 | ▲ +64.83% | ▲ +63.71% | $12.17 (+46.10%) |
May 12, 2026 24w ago | 8-K | $6.53 $12.01 | ▲ +83.92% | ▲ +79.48% | $12.17 (+86.37%) |
Apr 23, 2026 26w ago | DEFA14A | $4.46 $12.90 | ▲ +189.24% | ▲ +184.16% | $12.17 (+172.87%) |
Mar 19, 2026 31w ago | Press Release | $4.76 $7.83 | ▲ +64.50% | ▲ +50.08% | $12.17 (+155.67%) |
Mar 17, 2026 31w ago | Press Release | $4.95 $7.75 | ▲ +56.57% | ▲ +45.04% | $12.17 (+145.86%) |
Mar 12, 2026 32w ago | Press Release | $5.03 $8.23 | ▲ +63.62% | ▲ +52.92% | $12.17 (+141.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers